cervical
-
Roche acquires mtm laboratories, expands offering in cervical cancer testing
Roche announced that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. mtm develops in vitro diagnostics with a focus on early detection and diagnos…
cervical | 19 July 2011
-
Advaxis to conduct cervical cancer trial in India
Advaxis receives formal permission from the Drugs Controller General India (DCGI) to conduct a phase two clinical trial of ADXS11-001, the company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progress…
cervical | 16 August 2010
-
Health Leaders Convene in Korea to Save Women’s Lives
The International Vaccine Institute (IVI) has convened a symposium of 150 experts, policymakers, and decision makers from more than 36 countries from the Asia-Pacific and Middle East regions. This is to develop solutions to expand vaccination program…
cervical | 11 June 2009
-
Qiagen: Cervical Cancer Screening
Qiagen and the Chittaranjan National Cancer Institute (CNCI) have announced a collaboration to establish a cervical cancer screening program for women in Kolkata, India. The former will provide its diagnostic tests for the human papillomavirus (HPV).…
cervical | 05 May 2009
-
HPV Testing Reduces Deaths from Cervical Cancer
Results from an eight-year trial involving more than 130,000 women has been published. It demonstrates that in low-resource settings a single round of Human Papilloma Virus (HPV) testing significantly reduces the numbers of advanced cervical cancers …
cervical | 10 April 2009
-
MSD India launches country’s first HPV vaccine
MSD Pharmaceuticals (India), the local affiliate of Merck has announced the launch of Gardasil [Quadrivalent Human Papillomavirus (Types 6, 11, 16 & 18) Vaccine], India’s first vaccine to help prevent cervical cancer caused by the HPV types contain…
cervical | 17 October 2008
-
Predicting cervical disease developing countries
A new HPV test developed by Qiagen specifically for use in regions of the world with scarce resources is “substantially†more accurate in identifying women with cervical disease than the current methods (Pap testing and visual inspection) in thes…
cervical | 24 September 2008
-
Ending cervical cancer featured at summit
Qiagen was featured this week for its efforts to eliminate cervical cancer at the 14th annual Global Summit of Women in Hanoi, Vietnam. CEO Peer Schatz came to this prominent international platform to issue a call to other leaders in business, NG…
cervical | 09 June 2008
-
Vaccine Advances On Cervical Cancer Prevention
Vaccine technology update on cervical cancer.
cervical | 01 September 2007
-
Trial: GSK’s Cervical Cancer Candidate Vaccine Protects Against Lesions Caused By Cancer-Causing Virus Types
Results from an interim analysis of a Phase III study shows that Cervarix, the GlaxoSmithKline (GSK) cervical cancer candidate vaccine, provides up to 100 percent protection against advanced pre-cancerous lesions caused by the most common types of hu…
cervical | 02 July 2007
